Adebrelimab plus apatinib and SOX (AASOX) as conversion therapy for borderline resectable gastric cancer: a single-arm, single-centre, exploratory phase II study
In this single-arm, exploratory phase II study, the combination of adebrelimab, apatinib, and SOX chemotherapy (AASOX) demonstrated efficacy as conversion therapy for borderline resectable gastric cancer by achieving a 35.5% intention-to-treat R0 resection rate with manageable toxicity, warranting further multicentre randomized evaluation.
Original paper licensed under CC BY 4.0 (https://creativecommons.org/licenses/by/4.0/). This is an AI-generated explanation of the paper below. It is not written or endorsed by the authors. For technical accuracy, refer to the original paper. Read full disclaimer
Imagine the human body as a bustling city, and cancer as a group of unruly squatters who have built a massive, fortified bunker right in the middle of a busy intersection. In the world of gastric (stomach) cancer, these squatters sometimes build their walls so high and their guards so numerous that the city's cleanup crew—the surgeons—can't just walk in and tear the bunker down without causing a disaster. This is what doctors call "borderline resectable" cancer: the tumor is technically there, but it's too tangled with vital roads (blood vessels) or surrounded by too many enemy outposts (lymph nodes) to be removed safely right now.
To fix this, scientists have been trying a strategy called "conversion therapy." Think of it like sending in a special negotiation team to shrink the bunker and scatter the guards before the cleanup crew ever arrives. This team usually uses three types of tools: chemotherapy (a heavy-duty demolition crew), anti-angiogenic drugs (which cut off the bunker's supply lines by blocking new blood vessels), and immunotherapy (which wakes up the city's own security forces, the immune system, to attack the squatters). The big question has always been: Can we combine all three of these tools into one super-team to shrink these stubborn tumors enough to make surgery possible, without causing too much chaos in the city?
This is exactly what a team of researchers in China set out to test. They focused on a specific, tough group of patients whose stomach cancers were at that "borderline" stage. They created a new three-part team they called "AASOX." It consists of Adebrelimab (the immune system booster), Apatinib (the supply-line blocker), and SOX (a standard chemotherapy mix of oxaliplatin and S-1). Their goal was to see if this heavy-hitting combination could shrink the tumors enough to allow for a clean, complete removal (known as an R0 resection) in patients who otherwise had no hope of surgery.
The study was a "single-arm" trial, meaning everyone got the same treatment, and they watched to see how many people could eventually make it to the operating room. They enrolled 31 patients with these difficult tumors. The results were promising. Out of the 31 people who started the treatment, 11 were able to undergo surgery, and remarkably, all 11 achieved a complete removal of the tumor with clear margins. This means the "R0 resection rate" for the whole group was 35.5%. In the world of these tough, borderline cases, turning a "no surgery" situation into a "successful surgery" for over a third of the patients is a significant step forward.
The treatment didn't just help with surgery; it also shrank the tumors significantly. Before surgery, the doctors looked at scans and found that 61.3% of the patients had a major reduction in tumor size (either the tumor disappeared completely or shrank by more than half). When they looked at the tissue under a microscope after surgery, they found that 18.2% of the patients who had surgery had almost no living cancer cells left behind, a result known as a "pathological complete response."
However, the researchers are very careful not to call this a "cure" or a finished victory. They point out that while the surgery success rate was high, the long-term survival data is still "immature." This means they haven't watched the patients long enough yet to know if this treatment will help them live significantly longer years down the road. Out of the 31 patients, 7 had passed away by the time the study ended, but all of them were in the group that didn't get surgery. While this suggests that getting the surgery might be the key to survival, the authors warn that this is just a hint, not a proven fact, because the group that got surgery was already the "healthier" or "more responsive" group to begin with.
Safety was another major focus. Because this team uses three powerful drugs at once, the researchers expected some side effects. They found that 61.3% of patients experienced severe side effects (Grade 3 or higher), mostly related to low blood cell counts (neutropenia) and fatigue. However, there were no deaths caused by the treatment itself, and no major surgical complications occurred in the patients who did get operated on. The team also noted that they stopped the supply-blocker drug (apatinib) a month before surgery to let the body's healing processes recover, which likely helped keep the surgery safe.
In the end, this study suggests that the AASOX combination is a powerful and feasible way to turn "borderline" stomach cancer cases into "operable" ones for a meaningful number of patients. It proves that this aggressive three-pronged attack can work. But the authors emphasize that this is just the beginning of the story. Because the study was small, done at only one hospital, and didn't have a control group to compare against, these results are "hypothesis-generating." They are a strong signal that says, "Keep going, this looks promising," but they aren't the final answer. To know for sure if this is the new standard of care, larger, multi-hospital studies with longer follow-up times are needed to confirm that this approach truly helps patients live longer, healthier lives.
Drowning in papers in your field?
Get daily digests of the most novel papers matching your research keywords — with technical summaries, in your language.